Recent Quotes (30 days)

You have no recent quotes
chg | %

Lupin Limited  

(Public, NSE:LUPIN)   Watch this stock  
Find more results for LUPIN
761.70
-6.75 (-0.88%)
Real-time:   12:08PM GMT+5:30
NSE real-time data - Disclaimer
Currency in INR
Range 761.35 - 778.95
52 week 496.40 - 811.00
Open 774.00
Vol. 567,545.00
Mkt cap 340.80B
P/E 32.18
Div/yield 4.00/0.42
EPS 23.67
Shares 447.41M
Beta     -
Inst. own     -
Jul 22, 2013
Q1 2014 LUPIN LTD Earnings Release Add to calendar
May 28, 2013
LUPIN LTD at Nomura India All Access Conference Add to calendar
May 8, 2013
Q4 2013 LUPIN LTD Investor Meet
May 8, 2013
Q4 2013 LUPIN LTD Earnings Release
Feb 22, 2013
LUPIN LTD Business Update
  

Key stats and ratios

Q1 (Mar '13) 2013
Net profit margin 16.00% 13.86%
Operating margin 20.16% 19.90%
EBITD margin - 23.76%
Return on average assets - 15.91%
Return on average equity - 28.52%
Employees 6,000 -
Carbon Disclosure Rating - -

Address

B/4 Laxmi Towers Bandra Kurla Complex, Bandra ( Santacruz (E)
MUMBAI, 400051
India
+91-22-66402222 (Phone)
+91-22-66402130 (Fax)

Website links

External links

Discussion Group - Google Finance

Description

Lupin Limited is a transnational pharmaceutical Company. The Company is engaged in producing a range of generic and branded formulations and bulk drugs. It manufactures Active Pharmaceutical Ingredients (APIs) and several drug formulations. Its product basket consists of formulations from Cephalosporins, CVS, CNS, Anti-Asthma, Anti-TB, Diabetology, Dermatology, GI, and other therapy segments. Its APIs products include Cephalexin, Cefaclor, Cefadroxil, Cefprozil, Rifaximin, Ethambutol, Pyrazinamide, Rifampicin, Rifabutin, Lisinopril, Simvastatin, Prasugrel, Levetiracetam, Lacosamide, Eslicarbazepine Acetate, Rasagiline Mesylate, Pregabalin, Flupirtine Maleate and Febuxostat. As on March 31, 2012, the Company had 19 subsidiaries. During the year ended March 31, 2012, the Company, through its wholly owned subsidiary Lupin Holdings B.V., Netherlands (LHBV), acquired 100% interest in subsidiaries, which includes Hormosan Pharma GmbH, Lupin Philippines Inc. and Lupin Mexico SA de CV.

Officers and directors

Desh Bandhu Gupta Executive Chairman of the Board
Shakti Chakraborty Group President - India Region Formulations & CIS
Vinod Dhawan President - AAMLA and Business Development
Alok Ghosh President - Technical Operations
Naresh Gupta President - API & Global TB
Rajender Kamboj President - Novel Drug Discovery & Development
Cyrus Karkaria President - Biotechnology
Divakar Kaza President - Human Resources
Ramesh Swaminathan President - Finance & Planning
Sunil Makharia Executive Vice President - Finance